California has selected Civica as its insulin manufacturing partner, with the company now set to manufacture insulins for the state’s CalRx Biosimilar Insulin Initiative. CalRx will work with Civica to provide the most-used short- and long-acting insulins at planned prices of no more than $30 per 10ml vial and $55 for a box of five 3ml pre-filled pens.
Civica’s candidates are currently awaiting approval from the US Food and Drug Administration and are expected to reach the market in 2024
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?